Navigation Links
Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
Date:6/23/2009

Continuing Supplies Will Be Used For NDA and to Complete Current Phase 3 Trial of Naturlose(R) for Type 2 Diabetes

BETHESDA, Md., June 23 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has received its first full-scale production batch of cGMP (FDA Current Good Manufacturing Practice) D-tagatose, USP (U.S. Pharmacopeia) grade. One metric ton of drug was received from the manufacturer, Inalco S.p.A., of Italy. Spherix will use the tagatose in the process of satisfying the CMC (Chemistry, Manufacturing and Control) requirements of its NDA (New Drug Application) to the U.S. FDA. This batch, as well as subsequent batches, will also be used in the on-going Phase 3 clinical trial evaluating the effectiveness and safety of Naturlose as a treatment for Type 2 diabetes.

"Receiving this delivery of D-tagatose from Inalco is a noteworthy event for Spherix as it signifies achievement of several important milestones," said Dr. Claire Kruger, CEO of Spherix. "First, it demonstrates the full-scale cGMP process will be used to produce drug for marketing purposes and for use by patients in our Phase 3 clinical trial. Second, as part of this process, a DMF (Drug Master File) has been submitted to the FDA and Spherix has a Letter of Authorization to refer to the DMF in its NDA. Finally, it demonstrates Spherix's ability to use multiple sources to deliver the high volume of doses of Naturlose(R) that would be needed to meet patient demands should we receive FDA approval. The Company has enough drug to complete all of its clinical trials involving Naturlose as a novel and natural option to treat Type 2 diabetes."

'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Spherix Announces 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... positions Company to ... quarter of this year, ROCKVILLE, Md., Sept. 19 ... has completed enrollment of healthy,volunteers in a Phase IIa ... vaccine. The Phase IIa randomized, placebo,controlled clinical trial is ...
... Thirty seven medical,experts in psychiatry from across the ... urgent action to optimize services for people with ... or bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal ... Mental Disorders: Clinical,Policy, and Research Challenges which was ...
... NEP ),today announced that the Company has received ... indicating that the Company is not in,compliance with certain ... the AMEX Company Guide. Specifically, AMEX noted the,Company,s failure ... relating to stockholders, equity of less than $6,000,000 and ...
Cached Biology Technology:Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 2Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 3Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 4Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3Nephros Receives Non-Compliance Notification from AMEX 2Nephros Receives Non-Compliance Notification from AMEX 3
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... at the Ruhr-Universitt Bochum (RUB) have launched a new ... in promoting neuronal survival. The team of Prof Dr ... Department of Molecular Cell Biology, is looking for new ... Fox Foundation finances this research project with 125,000 US ...
... Discovery Fund (LSDF) today announced $1.1 million in ... and non-profit organizations to foster the translation of ... marketplace. Two of the five new ... invented within Washington-based companies. HeatFlow Technologies (principal investigator ...
... Tech leaders close out 2013 with beneficial ... (NASDAQ: SYMC ), Avago Technologies Limited (NASDAQ: ... ) and Apple Inc. (NASDAQ: AAPL) NXT-ID, Inc. ... Its Newly Formed Advisory Board And Shows First Images of ...
Cached Biology News:Life Sciences Discovery Fund announces R&D grants 2Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 2Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 3Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 4Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 5Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 6
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: